CA-SENTINELONE
10.5.2021 18:14:04 CEST | Business Wire | Press release
SentinelOne , the autonomous cybersecurity platform company, today announced it has been positioned by Gartner as a Leader in the 2021 Magic Quadrant for Endpoint Protection Platforms1 . SentinelOne believes the placement is a testament to the company’s innovative Singularity XDR platform and scaled go-to-market execution in record time. We believe this accomplishment signifies unrivaled product-market fit, innovation, and superb customer experience across a diverse set of customer profiles.
“Modern society is digital, and every place where data resides is vulnerable. Human-powered products simply cannot keep up with the exponentially growing threat landscape. Our AI-powered technology is the automated solution to modern day cyberattacks,” said Tomer Weingarten, CEO and Co-founder, SentinelOne. “We believe being named a Leader in the Gartner Magic Quadrant validates our approach and aligns with the market traction we’re experiencing. I am proud our team continues to deliver innovation, scale, and growth – all while keeping our customers protected.”
“SentinelOne is experiencing hypergrowth new logo adoption as well as module expansion from our existing customer base,” said Nicholas Warner, COO, SentinelOne. “We continue to outperform next-gen and legacy EPP vendors around the globe in comparative evaluations, demonstrating our ability to address cybersecurity at the pace and scale needed by modern businesses of all sizes to defeat attacks at machine speed.”
With excellent scores across EDR , EPP , and MDR in Gartner Peer Reviews, SentinelOne continues to deliver best-in-class customer satisfaction to its rapidly expanding global customer base of leading enterprises. In addition to being named a Leader in this year’s Magic Quadrant, SentinelOne received the highest overall rating and most verified reviews for the overall rating category in the 2020 Gartner Peer Insights ‘Voice of the Customer’: Endpoint Detection and Response Solutions report, and was recognized as a November 2019 Gartner Peer Insights Customers’ Choice for Endpoint Protection Platforms.
Gartner Peer Insights documents customer experience through verified ratings and peer reviews from enterprise IT professionals. As of April 23, 2021, SentinelOne reviews include the following:
“SentinelOne is a pioneering solution in endpoint protection with a rapid development lifecycle, best-of-breed platform support, and an unrivaled API.” - Information Security Manager, Manufacturing [read full review ]
“SentinelOne has become a main piece of our security portfolio. It was deployed to the majority of workstations and servers in our environment nearly overnight.” - Sr. Cybersecurity Analyst, Miscellaneous [read full review ]
“We looked at Cylance, Crowdstrike, Microsoft ATP Defender, Carbon Black and SentinelOne. Overall, S1 is an absolute game changer. These guys are disrupting traditional cyber security in a big way and will leave every CISO and their organization with little doubt about the right choice of EDR product.” - Senior Director, Cyber Security, Retail [read full review ]
“We couldn't be happier with SentinelOne! We did our own lab comparison of 11 products. SentinelOne came out on top easily!" [read full review ]
“SentinelOne has been critical in protecting our business. This platform provides not only next-gen AV, but also EDR. We actually made the decision to not renew our existing EDR platform because of SentinelOne's advanced EDR features.” - VP -- Detection and Response, Finance [read full review ]
- To register for our upcoming webinar on Wednesday, May 19th at 10:00 AM PDT, please visit: LINK
- Download a complimentary copy of the 2021 Gartner Magic Quadrant for Endpoint Protection platforms by visiting: LINK
Gartner does not endorse any vendor, product or service depicted in its research publications, and does not advise technology users to select only those vendors with the highest ratings or other designation. Gartner research publications consist of the opinions of Gartner’s research organization and should not be construed as statements of fact. Gartner disclaims all warranties, expressed or implied, with respect to this research, including any warranties of merchantability or fitness for a particular purpose.
Gartner Peer Insights reviews constitute the subjective opinions of individual end users based on their own experiences and do not represent the views of Gartner or its affiliates.
Gartner Peer Insights Customers’ Choice constitute the subjective opinions of individual end-user reviews, ratings, and data applied against a documented methodology; they neither represent the views of, nor constitute an endorsement by, Gartner or its affiliates.
About SentinelOne
SentinelOne is the leading cybersecurity solution encompassing AI-powered prevention, detection, response and hunting across endpoints, containers, cloud workloads, and IoT devices in a single autonomous platform. With SentinelOne, organizations gain transparency into everything happening across the network at machine speed – to defeat attacks, at every stage of the threat lifecycle. To learn more visit www.sentinelone.com or follow us at @SentinelOne , on LinkedIn or Facebook .
1 Gartner, Magic Quadrant for Endpoint Protection Platforms, Paul Webber, Peter Firstbrook, Rob Smith, Mark Harris, Prateek Bhajanka, 5 May 2021
View source version on businesswire.com: https://www.businesswire.com/news/home/20210510005705/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom